JP2013528622A - 炎症性障害の処置 - Google Patents

炎症性障害の処置 Download PDF

Info

Publication number
JP2013528622A
JP2013528622A JP2013513360A JP2013513360A JP2013528622A JP 2013528622 A JP2013528622 A JP 2013528622A JP 2013513360 A JP2013513360 A JP 2013513360A JP 2013513360 A JP2013513360 A JP 2013513360A JP 2013528622 A JP2013528622 A JP 2013528622A
Authority
JP
Japan
Prior art keywords
cadherin
antagonist
disorder
nucleic acid
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013513360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528622A5 (enExample
Inventor
ブレナー，マイケル，バリー
ノス，エリカ，ハイジ
チャン，スク，ギョン
Original Assignee
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド filed Critical ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド
Publication of JP2013528622A publication Critical patent/JP2013528622A/ja
Publication of JP2013528622A5 publication Critical patent/JP2013528622A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013513360A 2010-06-04 2011-06-03 炎症性障害の処置 Pending JP2013528622A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35150510P 2010-06-04 2010-06-04
US61/351,505 2010-06-04
PCT/US2011/039002 WO2011153397A2 (en) 2010-06-04 2011-06-03 Treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2013528622A true JP2013528622A (ja) 2013-07-11
JP2013528622A5 JP2013528622A5 (enExample) 2014-07-24

Family

ID=45067307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513360A Pending JP2013528622A (ja) 2010-06-04 2011-06-03 炎症性障害の処置

Country Status (7)

Country Link
US (1) US20130209476A1 (enExample)
EP (1) EP2575883B1 (enExample)
JP (1) JP2013528622A (enExample)
AU (1) AU2011261323A1 (enExample)
CA (1) CA2805270C (enExample)
IL (1) IL223385B (enExample)
WO (1) WO2011153397A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders
WO2016100301A1 (en) * 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US20200181649A1 (en) * 2016-07-14 2020-06-11 University Of Delaware Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524703A (ja) * 2003-04-23 2006-11-02 メダレックス インコーポレイテッド 炎症性腸疾患治療用の組成物及び治療方法
JP2007531761A (ja) * 2004-04-01 2007-11-08 エラン ファーマシューティカルズ，インコーポレイテッド ステロイド節約剤およびそれを使用する方法
WO2008140774A2 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
WO2009101059A2 (en) * 2008-02-11 2009-08-20 Novartis Ag Methods of using cadherin 11 (cdh11) antagonists
JP2009278976A (ja) * 2002-06-06 2009-12-03 Oncotherapy Science Ltd 肝細胞癌または結腸直腸癌に関連する遺伝子およびポリペプチド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
US7481999B2 (en) * 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US20050002919A1 (en) * 2003-06-09 2005-01-06 The Brigham And Women's Hospital, Inc. Cadherin directed molecular and cellular localization
US8802687B2 (en) * 2009-02-09 2014-08-12 Georgetown University Cadherin-11 inhibitors and methods of use thereof
US8877188B2 (en) * 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
CA2805267C (en) * 2010-05-04 2019-07-30 The Brigham And Women's Hospital, Inc. Detection and treatment of fibrosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009278976A (ja) * 2002-06-06 2009-12-03 Oncotherapy Science Ltd 肝細胞癌または結腸直腸癌に関連する遺伝子およびポリペプチド
JP2006524703A (ja) * 2003-04-23 2006-11-02 メダレックス インコーポレイテッド 炎症性腸疾患治療用の組成物及び治療方法
JP2007531761A (ja) * 2004-04-01 2007-11-08 エラン ファーマシューティカルズ，インコーポレイテッド ステロイド節約剤およびそれを使用する方法
WO2008140774A2 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
WO2009101059A2 (en) * 2008-02-11 2009-08-20 Novartis Ag Methods of using cadherin 11 (cdh11) antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015021117; ＰＬｏＳ　Ｍｅｄｉｃｉｎｅ ２（８）, 2005, ｅ１９９（ｐ．０７７１-０７８７） *

Also Published As

Publication number Publication date
WO2011153397A2 (en) 2011-12-08
EP2575883B1 (en) 2019-12-04
WO2011153397A3 (en) 2012-04-19
EP2575883A4 (en) 2014-01-22
CA2805270C (en) 2021-03-09
EP2575883A2 (en) 2013-04-10
US20130209476A1 (en) 2013-08-15
CA2805270A1 (en) 2011-12-08
AU2011261323A1 (en) 2013-01-24
IL223385B (en) 2020-06-30

Similar Documents

Publication Publication Date Title
JP6437946B2 (ja) 線維症の検出および処置
JP5850943B2 (ja) 狼瘡を治療又は予防するための組成物及び方法
US8877188B2 (en) Detection and treatment of non-dermal fibrosis
WO2015149056A1 (en) Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
JP6426001B2 (ja) 神経膠腫を治療するための組成物および方法
US10106601B2 (en) Inhibition of PLGF to treat philadelphia chromosome positive leukemia
EP2575883B1 (en) Treatment of inflammatory disorders
CN106029101A (zh) 生物材料和其治疗用途
JP2010532334A (ja) 腎疾患を処置するための化合物および方法
US20250297310A1 (en) Hematopoietic loss of y chromosome leads to cardiac fibrosis and dysfunction and is associated with death due to heart failure
AU2017200553B2 (en) Treatment of inflammatory disorders
US11097005B2 (en) Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
WO2022014703A1 (ja) 筋疾患の予防または治療剤
JP2007523895A (ja) 過剰な免疫グロブリン産生の治療としてのＢｒｉｇｈｔ機能の阻害方法
WO2025155710A1 (en) Methods of treating, ameliorating and/or preventing vascular inflammation and diseases/disorders associated with the same
HK1183322B (en) Cadherin-11 antagonist for the treatment of fibrosis
WO2010046474A2 (en) Chemoattractants inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160229